Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Over the next few years, Philips aims to double the number of its active cath labs in India with a special focus on improving accessibility to quality cardiac and neurovascular care in tier 2 and tier 3 cities
Subscribe To Our Newsletter & Stay Updated